Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
Back
Product details:
CAS
1110813-31-4
Purity
95%
Dacomitinib is a medication used to treat non small cell lung cancer with EGFR exon 19 deletion of exon 21 L858R substitution. Dacomitinib is an irreversible small molecule inhibitor of the activity of the human epidermal growth factor receptor family (EGFR/HER1, HER2, and HER4) tyrosine kinases.
Properties
Name
Dacomitinib
Smiles
COC=1C=C2N=CN=C(NC=3C=CC(F)=C(Cl)C3)C2=CC1NC(=O)/C=C/CN4CCCCC4
Targets
Please log in to see this information
Sold for research purposes under agreement from Pfizer Inc.
SDS
Dacomitinib | PF-00299804 | PF299 | PF299804
No data available
The compound has purity validated by NMR and/or LCMS methods.
1 mg
$37
2 mg
$39
5 mg
$41
10 mg
$43
15 mg
$45
20 mg
$48
25 mg
$53
30 mg
$55
35 mg
$58
40 mg
$60
45 mg
$63
50 mg
$65
75 mg
$68
100 mg
$POA
Quantity
1
Total amount
$ 41
Dacomitinib | PF-00299804 | PF299 | PF299804
No data available
The compound has purity validated by NMR and/or LCMS methods.
Target activity features
It should be emphasized that the product may be active against a larger number of targets than shown on the card. The information represented here refers to the targets with the largest value of pX or the targets with ΔpX less than 1.5 from the largest pX value.
CAS:1042385-75-0
0